Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SyB L-0501 + Rituximab in r/r DLBCL
NCT03372837Phase 3Completed
- Sponsor
- SymBio Pharmaceuticals
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bendamustine in diffuse large B-cell lymphoma (DLBCL), sponsored by SymBio Pharmaceuticals. Primary endpoint: Overall Response Rate at 30 weeks. Started Jan 2018; status: completed.
02
Drugs
bendamustine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03372837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03372837.